Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
- PMID: 19501928
- DOI: 10.1016/j.jhep.2009.03.019
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
Abstract
Background/aims: Non-alcoholic steatohepatitis (NASH) is a growing public health problem. Evaluation of risk factors for fibrosis in NASH will help to target resources to reduce development of cirrhosis. This study had two aims; the first to compile longitudinal histological data to characterize the natural history of fibrosis progression in NASH, and second, to identify predictive factors for progression to advanced fibrosis (stage 3 or greater) in NASH.
Methods: Subjects had to have a histological diagnosis compatible with NASH on their initial biopsy, received no intervention of proven histological benefit, and undergone two liver biopsies with at least an interval of one year between them.
Results: Ten studies were selected comprising 221 patients. 37.6% had progressive fibrosis over a mean follow-up interval of 5.3 years (SD, 4.2 years, median, 3.7 years, range 1.0-21.3 years). Proportional hazards regression analysis demonstrated that age (HR=0.98, p=0.009) and inflammation on initial biopsy (any inflammation, HR=2.5, p=0.001; grade 1, HR=2.5, p=0.001; grade 2, HR=2.4, p=0.003) are independent predictors of progression to advanced fibrosis. Other traditional parameters (e.g. obesity, diabetes, hypertension) were not statistically significant predictors.
Conclusions: Presence of inflammation on the initial biopsy and age are independent predictors of progression to advanced fibrosis in patients with NASH.
Similar articles
-
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1. J Hepatol. 2015. PMID: 25477264
-
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.Hepatology. 1999 Dec;30(6):1356-62. doi: 10.1002/hep.510300604. Hepatology. 1999. PMID: 10573511
-
Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension.Am J Gastroenterol. 2010 Feb;105(2):336-44. doi: 10.1038/ajg.2009.587. Epub 2009 Oct 27. Am J Gastroenterol. 2010. PMID: 19861959
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
The natural history of non-alcoholic fatty liver disease.Dig Dis. 2010;28(1):162-8. doi: 10.1159/000282081. Epub 2010 May 7. Dig Dis. 2010. PMID: 20460906 Review.
Cited by
-
Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.J Agric Food Chem. 2024 Apr 17;72(15):8536-8549. doi: 10.1021/acs.jafc.3c08910. Epub 2024 Apr 4. J Agric Food Chem. 2024. PMID: 38575146
-
Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk.Front Immunol. 2024 Feb 28;15:1337241. doi: 10.3389/fimmu.2024.1337241. eCollection 2024. Front Immunol. 2024. PMID: 38481995 Free PMC article.
-
The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review.Med Pharm Rep. 2024 Jan;97(1):12-25. doi: 10.15386/mpr-2629. Epub 2024 Jan 29. Med Pharm Rep. 2024. PMID: 38344336 Free PMC article. Review.
-
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?Metabolites. 2024 Jan 8;14(1):40. doi: 10.3390/metabo14010040. Metabolites. 2024. PMID: 38248843 Free PMC article. Review.
-
The Combination of Remnant Cholesterol and Waist Circumference Offers Predictive Value for Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study from a Medical Examination Center.Diabetes Metab Syndr Obes. 2023 Nov 2;16:3459-3469. doi: 10.2147/DMSO.S429963. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37937236 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical